Home » FightingDrugFailure » The Fighting Drug Failure Publications

Publications of the Initial Training Network Fighting Drug Failure

 

  • CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations. Province M, Goetz M, et al. Clinical Pharmacology and Therapeutics 2013 Sep 23 [Epub ahead of print]
  • Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Hoppe R, Achinger-Kawecka J, et al. Eur J Cancer. 2013; Aug 19 (Epub ahead of print)    19.08.2013
  • ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Magdy T, Arlanov R, Winter S,et al. Pharmacogenomics. 2013 Sep;14(12):1433-48.
  • The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7. Precht JC, Schroth W, et al. Drug Metab Dispos. 2013 Aug 21. [Epub ahead of print].
  • Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Pilar Saladores, Jana Precht, et al. Expert Review of Molecular Diagnostics. 2013, May Vol. 13, No. 4, Pages 349-365.
  • Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. French JD, Ghoussaini M, et al. Am J Hum Genet. 2013 Apr 4;92(4):489-503.
  • Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Garcia-Closas M, Couch FJ, et al. Nat Genet. 2013 Apr;45(4):392-8, 398e1-2.
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Bojesen SE, Pooley et al. Nat Genet. 2013 Apr;45(4):371-84, 384e1-2.
  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Michailidou K, Hall P, et al. Nat Genet. 2013 Apr;45(4):353-61, 361e1-2.
  • 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Lambrechts D, Truong T, et al. Hum Mutat 2012 Jul;33(7):1123-32 Epub 2012 Apr 30.
  • Genome-wide association analysis identifies three new breast cancer susceptibility loci. Ghoussaini M, Fletcher O, et al. Nat Genet 2012 Jan 22;44(3):312-8.
  • Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Mürdter TE, Kerb R, et al. Hum Mol Genet 21:1145-54, 2012.
  • A Common Variant at the TERT-CLPTM1L Locus is Associated with Estrogen Receptor-Negative Breast Cancer. Haiman CA, Chen GK et al. Nat Genet 2011 Oct 30 ; 43(12):1210-4 [Epub ahead of print].
  • Common Breast Cancer Susceptibility Loci are Associated with Triple Negative Breast Cancer. Stevens KN, Vachon CM, et al. Cancer Res 2011; 71:6240-6249.
  • A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Filipits M, Rudas M, et al. Clin Cancer Res 2011; 17:6012-6020.
  • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Antoniou AC, Wang X, et al. Nat Genet 2010 Oct;42(10):885-92 [Epub 2010 Sep 19].
  • Mechanism of Estrogen Receptor Antagonism Towards p53: Implications in Breast Cancer Therapeutic Response and Stem Cell Regulation. Konduri SD, Medisetty R, et al. Proc Natl Acad Sci USA 2010 Aug 24;107(34):15081-6. [Epub 2010 Aug 9].
  • CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification. Schroth W, Hamann U, et al. Clin Cancer Research 2010, 16:4468-4477 [Epub 2010 Jul 20].
  • Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Breast Cancer Treated With Tamoxifen. Schroth W, Goetz MP, et al.  Journal of the American Medical Association 2009, 302:1429-1436.
  • Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Ahmed S, Thomas G, et al. Nature Genetics 2009 May;41(5):585-90 [Epub 2009 Mar 29].
  • Metformin and Cancer: From the Old Medicine Cabinet to Pharmacological Pitfalls and Prospects. Emami Riedmaier A, Fisel P,et al. Trends Pharmacol. Sci. 2013 Feb;34(2):126-3.
  • Organic Anion Transporters and Their Implications in Pharmacotherapy    Emami Riedmaier A, Nies AT, et al. Pharmacol Rev. 2012 Jul;64(3):421-49.
  • OCT (SLC22A) and OCTN Family. Stocker, S, Emami Riedmaier, A., et al. Pharmacogenomics of Human Drug Transporters: Clinical Impacts: John Wiley & Sons, Inc. USA. May 2013    171-209. Print ISBN: 9780470927946. Online ISBN: 9781118353240.
  • Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Nies AT, Niemi M, et al. Genome Med (2013);5:1.
  • Multidrug resistance proteins of the ABCC subfamily. Nies AT, Lang T. In: You G, Morris ME, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ, USA: John Wiley, in press.
  • The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy. Justenhoven C, Obazee O, Brauch H. Pharmacogenomics. 2012 Apr;13(6):659-75.
  • The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Justenhoven C, Obazee O, et al. Breast Cancer Res Treat. 2012 Jan;131(1):347-50.
  • The UGT1A6_19_GG genotype is a breast cancer risk factor.    Justenhoven C, Obazee O, et al. Front Genet. 2013 Jun 11;4:104.
  • Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. Obazee O, Justenhoven C, et al. Breast Cancer Res Treat. 2013 Apr;138(2).
  • Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Carr DF, Chaponda M, Jorgensen A, et al. Clin Infect Dis. 2013 May;56(9):1330-9.
  • Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. John Farrell, Maike Lichtenfels, et al. J Allergy Clin Immunol. 2013 Aug;132(2):493-5.
  • In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Faviel Gonzalez-Galarza, Catherine Bell, et al. Genome Medicine 2012 Jun. 25;4(6):51.
  • Transport of gabapentin by LAT1 (SLC7A5). David Dickens, Steven D. Webb,  et al. Biochem Pharmacol. 2013 Jun 1;85(11):1672-83.
  • Molecular Interactions between NAFLD and Xenobiotic metabolism. Naik A, Belic A, Zanger UM, Rozman D. Front Genet. 2013 Jan 22;4:2. Epublication 25.1.2013.
  • Genomic aspects of NAFLD pathogenesis. Naik A, Košir R, Rozman D. Genomics. 2013 Aug;102(2):84-95.
  • Analysis of the steady-state relations and control-algorithm characterisation in a mathematical model of cholesterol biosynthesis. Ales Belic, Jure Acimovic, et al. Simulation Modelling Practice and Theory. 2013 Apr. Volume 33, 18-27.
  • Cytochrome P450s in the synthesis of cholesterol and bile acids-from mouse models to human diseases. Lorbek G, Lewinska M, Rozman D. The FEBS Journal. FEBS J. 2012 May;279(9):1516-33.
  • High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Sokolenko AP, Iyevleva AG, et al. Int J Cancer. 2012 Jun 15;130(12):2867-73.